Seeking Alpha

More on Sarepta Therapeutics' (SRPT) Q1: Nothing particularly groundbreaking regarding...

More on Sarepta Therapeutics' (SRPT) Q1: Nothing particularly groundbreaking regarding eteplirsen in the PR. The company says it is "encouraged" by its correspondence with the FDA and is "finalizing" its response to requests for further information (I, II). A $6.7M decrease in government contract revenue is blamed for the higher (Y/Y) operating loss. Operating expenses were higher as the company expands its Duchenne muscular dystrophy program. Shares +1.24% premarket.
Comments (2)
  • simp08801
    , contributor
    Comments (6) | Send Message
     
    "Nothing particularly groundbreaking"? The CEO stated he expects to meet with FDA on new dmd data submission by end of Q2. This meeting was assumed to occur as late as Q4. Schedule on FDA final determination of filing of AA application appears materially condensed based on CEO comments.
    9 May 2013, 09:03 AM Reply Like
  • whaddyamean?
    , contributor
    Comments (514) | Send Message
     
    "Nothing particularly groundbreaking" = windbreaking
    9 May 2013, 09:09 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector